Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, Japan
In Japan, the traditional method for measuring plasma aldosterone concentration (PAC) was radioimmunoassay (RIA), which had several challenges, including poor traceability of certified reference materials and reduced detection sensitivity at low concentrations. To overcome these issues, a chemilumin...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2024-09-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0227/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591915741085696 |
|---|---|
| author | Ken-ichiro Honma Yoshiro Nakayama Atsuko Tamaki Moriyuki Uehara Taiki Teruya Takamitsu Yabiku Yohei Ishiki Ken Yonaha Rei Chinen Tsugumi Uema Shiki Okamoto Hiroaki Masuzaki |
| author_facet | Ken-ichiro Honma Yoshiro Nakayama Atsuko Tamaki Moriyuki Uehara Taiki Teruya Takamitsu Yabiku Yohei Ishiki Ken Yonaha Rei Chinen Tsugumi Uema Shiki Okamoto Hiroaki Masuzaki |
| author_sort | Ken-ichiro Honma |
| collection | DOAJ |
| description | In Japan, the traditional method for measuring plasma aldosterone concentration (PAC) was radioimmunoassay (RIA), which had several challenges, including poor traceability of certified reference materials and reduced detection sensitivity at low concentrations. To overcome these issues, a chemiluminescent enzyme immunoassay (CLEIA) for PAC measurement was introduced in April 2021 and the Japan Endocrine Society published new guidelines for primary aldosteronism (PA). This study aimed to evaluate the impact of the transition from RIA to CLEIA for PAC measurement on PA diagnosis. Data from 190 patients admitted to the Second Department of Internal Medicine, University of the Ryukyus Hospital, between April 2012 and March 2021 were analyzed. Patients who were diagnosed with PA underwent adrenal venous sampling. The PAC measured by RIA (PAC(RIA)) was converted to the estimated PAC measured by CLEIA (ePAC(CLEIA)) using a conversion formula. The present study evaluated the discordance rates in diagnoses based on screening (SC), captopril challenge test (CCT), saline infusion test (SIT), and diagnosis of PA between results judged by PAC(RIA) according to the previous guidelines and those judged by ePAC(CLEIA) according to the new guidelines. The results revealed discordant diagnosis rates of 6.4% for SC and 10.1% for CCT, with no discordance for SIT. The discordant diagnosis rate for PA was 3.7%. Our study reveals the challenges in establishing appropriate diagnostic criteria for PA using PAC(CLEIA) and highlights the demand for further research on provisionally positive categories. |
| format | Article |
| id | doaj-art-7a654cf94f49449d8ff46be752ce9e15 |
| institution | Kabale University |
| issn | 1348-4540 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | The Japan Endocrine Society |
| record_format | Article |
| series | Endocrine Journal |
| spelling | doaj-art-7a654cf94f49449d8ff46be752ce9e152025-01-22T05:20:11ZengThe Japan Endocrine SocietyEndocrine Journal1348-45402024-09-0171989590610.1507/endocrj.EJ24-0227endocrjImpact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, JapanKen-ichiro Honma0Yoshiro Nakayama1Atsuko Tamaki2Moriyuki Uehara3Taiki Teruya4Takamitsu Yabiku5Yohei Ishiki6Ken Yonaha7Rei Chinen8Tsugumi Uema9Shiki Okamoto10Hiroaki Masuzaki11Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanDivision of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology, Second Department of Internal Medicine, Graduate School of Medicine, University of the Ryukyus, Okinawa 903-0215, JapanIn Japan, the traditional method for measuring plasma aldosterone concentration (PAC) was radioimmunoassay (RIA), which had several challenges, including poor traceability of certified reference materials and reduced detection sensitivity at low concentrations. To overcome these issues, a chemiluminescent enzyme immunoassay (CLEIA) for PAC measurement was introduced in April 2021 and the Japan Endocrine Society published new guidelines for primary aldosteronism (PA). This study aimed to evaluate the impact of the transition from RIA to CLEIA for PAC measurement on PA diagnosis. Data from 190 patients admitted to the Second Department of Internal Medicine, University of the Ryukyus Hospital, between April 2012 and March 2021 were analyzed. Patients who were diagnosed with PA underwent adrenal venous sampling. The PAC measured by RIA (PAC(RIA)) was converted to the estimated PAC measured by CLEIA (ePAC(CLEIA)) using a conversion formula. The present study evaluated the discordance rates in diagnoses based on screening (SC), captopril challenge test (CCT), saline infusion test (SIT), and diagnosis of PA between results judged by PAC(RIA) according to the previous guidelines and those judged by ePAC(CLEIA) according to the new guidelines. The results revealed discordant diagnosis rates of 6.4% for SC and 10.1% for CCT, with no discordance for SIT. The discordant diagnosis rate for PA was 3.7%. Our study reveals the challenges in establishing appropriate diagnostic criteria for PA using PAC(CLEIA) and highlights the demand for further research on provisionally positive categories.https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0227/_html/-char/enhypertensionprimary aldosteronismplasma aldosterone concentrationradioimmunoassaychemiluminescent enzyme immunoassay |
| spellingShingle | Ken-ichiro Honma Yoshiro Nakayama Atsuko Tamaki Moriyuki Uehara Taiki Teruya Takamitsu Yabiku Yohei Ishiki Ken Yonaha Rei Chinen Tsugumi Uema Shiki Okamoto Hiroaki Masuzaki Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, Japan Endocrine Journal hypertension primary aldosteronism plasma aldosterone concentration radioimmunoassay chemiluminescent enzyme immunoassay |
| title | Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, Japan |
| title_full | Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, Japan |
| title_fullStr | Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, Japan |
| title_full_unstemmed | Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, Japan |
| title_short | Impact of the transition from radioimmunoassay (RIA) to chemiluminescent enzyme immunoassay (CLEIA) for the measurement of plasma aldosterone concentration (PAC) on the diagnosis of primary aldosteronism (PA) via retrospective analyses in Okinawa, Japan |
| title_sort | impact of the transition from radioimmunoassay ria to chemiluminescent enzyme immunoassay cleia for the measurement of plasma aldosterone concentration pac on the diagnosis of primary aldosteronism pa via retrospective analyses in okinawa japan |
| topic | hypertension primary aldosteronism plasma aldosterone concentration radioimmunoassay chemiluminescent enzyme immunoassay |
| url | https://www.jstage.jst.go.jp/article/endocrj/71/9/71_EJ24-0227/_html/-char/en |
| work_keys_str_mv | AT kenichirohonma impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT yoshironakayama impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT atsukotamaki impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT moriyukiuehara impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT taikiteruya impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT takamitsuyabiku impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT yoheiishiki impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT kenyonaha impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT reichinen impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT tsugumiuema impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT shikiokamoto impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan AT hiroakimasuzaki impactofthetransitionfromradioimmunoassayriatochemiluminescentenzymeimmunoassaycleiaforthemeasurementofplasmaaldosteroneconcentrationpaconthediagnosisofprimaryaldosteronismpaviaretrospectiveanalysesinokinawajapan |